Skip to content

Exelixis EXEL Other accrued liabilities

Other accrued liabilities at other companies

Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Summit Therapeutics logo
Summit TherapeuticsSMMT
Incyte logo
IncyteINCY
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's other accrued liabilities?
Exelixis (EXEL) reported other accrued liabilities of $100.29M in Q1 2026.
How has Exelixis's other accrued liabilities changed year-over-year?
Exelixis's other accrued liabilities decreased by 20.1% year-over-year, from $125.55M to $100.29M.
What is the long-term trend for Exelixis's other accrued liabilities?
Over 5 years (2020 to 2025), Exelixis's other accrued liabilities has grown at a 23.0% compound annual growth rate (CAGR), from $44.45M to $125.38M.